Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy Meeting Abstract
| Authors: | Park, W.; O'Connor, C.; Chou, J. F.; Schwartz, C.; Varghese, A. M.; Larsen, M.; Balogun, F.; Brenner, R.; Yu, K. H.; Diguglielmo, E.; Umeda, S.; Karnoub, E.; Keane, F.; Zhang, H.; Joshi, S. S.; Riaz, N.; Kelsen, D. P.; Capanu, M.; Iacobuzio-Donahue, C. A.; O'Reilly, E. M. |
| Abstract Title: | Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.4140 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: 4140 -- This meeting was also held virtually -- Source: Cinahl |
Altmetric
Citation Impact
BMJ Impact Analytics
